复方银杏通脉口服液联合厄贝沙坦治疗高血压的临床研究

目的探讨复方银杏通脉口服液联合厄贝沙坦治疗高血压的临床疗效。方法选取2017年5月—2017年11月在深圳市龙华区中心医院进行诊治的106例高血压患者,随机分为对照组和治疗组,每组各53例。对照组口服厄贝沙坦片,起始剂量为0.15 g/次,根据病情可增至0.3 g/次,1次/d;治疗组在对照组治疗基础上口服复方银杏通脉口服液,10 mL/次,3次/d。两组患者均连续治疗4周。观察两组的临床疗效,比较两组治疗前后24 h平均收缩压(mSBP)、24 h平均舒张压(mDBP)、临床症状积分、单核细胞趋化蛋白-1(MCP-1)、可溶性凝集素样氧化型低密度脂蛋白受体-1(sLOX-1)、基质金属蛋白酶-9(MMP-9)、内皮素(ET)、一氧化氮(NO)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为81.13%、98.11%,两组比较差异有统计学意义(P0.05)。治疗后,两组24 h mSBP、24 h mDBP、头痛积分、耳鸣积分、头晕积分均较治疗前显著降低,同组治疗前后比较差异有统计学意义(P0.05);治疗后,治疗组24 h mSBP、24 h mDBP、头痛积分、耳鸣积分、头晕积分水平显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清MCP-1、sLOX-1、MMP-9、ET-1水平均显著降低,但NO水平显著增高,同组治疗前后比较差异有统计学意义(P0.05);治疗后,治疗组MCP-1、sLOX-1、MMP-9、ET-1水平低于对照组,NO水平高于对照组,两组比较差异具有统计学意义(P0.05)。结论复方银杏通脉口服液联合厄贝沙坦治疗高血压具有较好的临床疗效,可有效降低患者血压,改善临床症状,还可改善血清因子水平,具有一定的临床推广应用价值。

Clinical study on Compound Yinxing Tongmai Oral Liquid combined with irbesartan in treatment of hypertension

Objective To explore the clinical efficacy of Compound Yinxing Tongmai Oral Liquid combined with irbesartan in treatment of hypertension. Methods Patients (106 cases) with hypertension in Shenzhen Longhua District Central Hospital from May 2017 to November 2017 were randomly divided into control (53 cases) and treatment (53 cases) groups. Patients in the control group were po administered with Irbesartan Tablets, and the initial dosage was 0.15 g/time, which could be increased to 0.3 g/time, once daily. Patients in the treatment group were po administered with Compound Yinxing Tongmai Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of 24 h mSBP, 24 h mDBP, clinical symptom integral, MCP-1, sLOX-1, MMP-9, ET, and NO in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.13% and 98.11%, respectively, and there was difference between two groups (P < 0.05). After treatment, 24 h mSBP, 24 h mDBP, headache integral, tinnitus integral, and dizziness integral in the two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). After treatment, 24 h mSBP, 24 h mDBP, headache integral, tinnitus integral, and dizziness integral in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, MCP-1, sLOX-1, MMP-9, and ET-1 in two groups were significantly reduced, but NO was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, MCP-1, sLOX-1, MMP-9, and ET-1 in the treatment group were lower than those in the control group, but NO was significantly higher than that in the control group, and there was difference between two groups (P < 0.05). Conclusion Compound Yinxing Tongmai Oral Liquid combined with irbesartan has remarkable clinical effect in treatment of hypertension, and can effectively reduce the blood pressure, and can improve the clinical symptoms and serum factor levels, which has a certain clinical application value.